Parabilis raises $670M in record-setting Nasdaq debut to fund cancer drug development

Parabilis completed a $670 million initial public offering on the Nasdaq, establishing the largest biotech debut in the exchange’s history.

The offering drew strong investor demand even as attention was focused on upcoming AI company listings.

Proceeds from the IPO are earmarked for advancing the company’s lead cancer therapy and expanding its pipeline.

Analysts view the successful float as a positive signal for the biotech sector’s financing environment.